This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ARTHUR C. CURTIS, M.D.; E. RICHARD HARRELL, JR., M.D.

AMA Arch Derm Syphilol. 1952;66(6):676-690.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Systemic blastomycosis usually is fatal. In a review of the literature Martin and Smith¹ noted a mortality of 92% in patients who had been followed for two years or longer. Cutaneous blastomycosis rarely causes death, but untreated lesions may be present for many years.

Since the synthesis of a group of compounds known as aromatic diamidines by Ashley and his co-workers² in the course of their studies on trypanocidal drugs, a surprisingly large number of other therapeutic effects have been shown both in vitro and in vivo. The first hint that the aromatic diamidines might be fungistatic came from the studies of Elson³ who used one member of this group, "propamidine" (4,4'-diamidinodiphenyloxypropane hydrochloride) in several in vitro experiments with some of the organisms responsible for the superficial and deep mycoses. The experiments with Blastomyces dermatitidis showed effective fungistatic properties in dilutions as low as 0.075 mg. of . . . [Full Text PDF of this Article]

Author Affiliations
ANN ARBOR, MICH.

From the Department of Dermatology and Syphilology, University of Michigan Medical School.

Footnotes
Read at the Seventy-Second Annual Meeting of the American Dermatological Association, Colorado Springs, Colo., April 24, 1952.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?